Let me pull recent stock price action and the latest news/analyst commentary heading into the print.I have what I need. Let me write the preview.
Microchip reports its first full quarter of fiscal 2027 into a tape that has turned sharply against it. This is a "prove the recovery is real and accelerating" quarter: the company is guiding to a huge YoY rebound, but the stock has round-tripped a large chunk of its spring rally, and expectations for the September-quarter guide — not the June print — are what will move the shares.
On the May 7 call, management guided the June quarter to:
| Metric | FQ1'27 Guidance | Midpoint | vs. FQ4'26 actual |
|---|---|---|---|
| Net sales | $1.442–1.469B | $1.456B | +11.0% QoQ, +35.3% YoY |
| Non-GAAP gross margin | 62.25%–63.25% | ~62.75% | vs. 61.6% |
| Non-GAAP operating margin | 33.0%–34.5% | ~33.75% | vs. 30.6% |
| Non-GAAP EPS | $0.67–$0.71 | $0.69 | vs. $0.57 |
| Non-GAAP OpEx | 28.75%–29.25% of sales | — | vs. 31.0% |
Context on how they've been trending: last quarter revenue of $1.311B came in above the high end of guidance (+35.1% YoY, +10.6% QoQ) and non-GAAP EPS of $0.57 beat the $0.50 midpoint by $0.07. MCHP has been consistently beating its own conservative guide as the cyclical recovery plays out, so the June result itself is likely a formality — the debate is about the trajectory from here.
Management pointedly declined to put a number on the September quarter in May, but the setup they described was bullish: - Book-to-bill "well above 1," with March-quarter backlog much higher entering June. - April was the largest booking month in nearly four years. - CFO Bjornholt said September-quarter backlog was already higher than the June-quarter backlog was at the same point. - On the call, an analyst flagged Street consensus for September at only +5–6% QoQ.
Given those hints, anything in-line-to-below a high-single-digit sequential guide could disappoint the bulls who bought the acceleration story; a double-digit sequential guide would validate it. This is the single most important data point in the release.
The key gating factor is capacity underutilization, which was a $46.6M drag last quarter. CFO's math: add that back and MCHP is essentially at its 65% long-term target. Watch for (a) the size of the underutilization charge as fabs ramp, and (b) confirmation that inventory-reserve charges have truly normalized (they said this happened in March). Front-end fabs are running ~35% internal, back-end ~70% internal, so the internal fab ramp is the bigger margin lever from here.
A notable shift in tone last quarter: lead times are extending, and management warned that "in another quarter or so, there could be nothing available in 4–6 weeks." Constraints are broadening across substrates (12-month shelf life), OSAT capacity, and foundry nodes (70–80% of nodes described as tight). Meanwhile MCHP is deliberately holding pricing to rebuild customer relationships while competitors raise prices — a share-gain thesis but a near-term margin choice. Look for any pivot on pricing into H2 and whether supply constraints are capping upside/backlog conversion.
Brian McCarson's Data Center Solutions unit is the growth narrative: PCIe Gen 6 switch entering production ramp at the end of the June quarter, a new Gen 6 PCIe retimer entry (already a major OEM design win displacing a competitor), plus storage and CXL/PCIe memory controllers. Six Gen 6 switch design wins pre-production. Investors will want quantification — management has promised (but not yet delivered) a cleaner breakout of data center / megatrend revenue. Any disclosure here would be a catalyst.
The chart tells you why this print is high-stakes. MCHP ran from a March low near $62 to a June intraday peak around $103 as the recovery narrative took hold — then reversed hard, closing $77.81 on Aug 5, roughly -24% off the June high. It gapped down to ~$71 on July 29 before partially recovering. Much of the July drawdown was sector-wide (SOXX fell in tandem), but MCHP has underperformed, suggesting the market is skeptical the acceleration can sustain at these valuations. That reset arguably lowers the bar into the print — but also signals that "in-line" won't be enough.
The most important sentences to read in the release won't be the June actuals — they'll be the September outlook and the gross-margin/underutilization commentary. Everything else is supporting evidence for whether this early-cycle recovery is broadening and accelerating, or just normalizing.
Note: figures above are non-GAAP unless stated; guidance and channel/backlog commentary are drawn from MCHP's May 7, 2026 FQ4'26 earnings release and call, the July 24 COO-departure 8-K, and market prices through Aug 5, 2026.